Company intelligence / Profile preview

PreTeL

Chattanooga, Tennessee, United Statespretelhealth.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Early results from ongoing NIH-funded clinical studies indicate that PreTeL’s Area Sensor platform can significantly improve prediction of preterm labor. The company aims to provide early warning monitoring for pregnancies at risk for spontaneous preterm birth, optimize labor induction with personalized Pitocin dosing, and improve outcomes for mothers and babies. Commercialization anticipated within 2–3 years based on current progress

Therapeutic areas: Women's Health
Modalities: DeviceAI-enabled digital health platform
Industry: Physiological Monitoring

Partnerships

NIH-funded research collaborations with Duke University & University of Rochester Medical Center

Beyond the preview

Go deeper on PreTeL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreTeL.

Explore the full profile